University of California San Francisco

Flavio Vincenti, MD

Flavio Vincenti - 144
Flavio
Vincenti
MD

Clinical Professor of Medicine and Surgery
Departments of Medicine and Surgery
Endowed Chair in Kidney Transplantation

Address

505 Parnassus Avenue, #M884D
San Francisco, CA 94117
United States

Email: [email protected]

ORCID: 0000-0002-6701-4680

Biography

I have been at UCSF since 1975 and on the faculty of the Department of Medicine in the division of Nephrology since 1976 and have been involved with the transplant service in patient care and clinical trials with novel immunosuppression drugs

Education

Institution Degree Dept or School End Date
University of California, San Francisco Residency School of Medicine

Board Certifications

American Board of Internal Medicine, Internal Medicine

American Board of Internal Medicine, Nephrology - Subspecialty

Clinical Expertise

Internal Medicine
Transplant Nephrology
Kidney Transplantation
Pancreas Transplantation
Living Kidney Donor Transplantation
End Stage Renal Disease (Kidney Failure)
Chronic Kidney Disease

In the News

Drug Provides Better Kidney Transplant Survival Rates Than Current Standard Of Care
January, 28, 2016 | UCSF Transplant Surgery
Walnut Creek Man Receives Gift of Life From Family --- For a Second Time
February, 09, 2015 | UCSF Transplant Surgery
Toward Personalized Medicine for Kidney Transplant Recipients
August, 27, 2014 | UCSF Transplant Surgery

Grants and Funding

  • Applying precision MEdicine to optimize desensitization with noveL bIOlogics or cellular theRApies in highly sensiTized kidney transplant patiEnts (AMELIORATE) | NIH | 2014-07-01 - 2024-05-31 | Role: Principal Investigator
  • General Clinical Research Center | NIH | 1974-12-01 - 2009-03-31 | Role: Co-Investigator

Research Interests

Transplant Nephrology

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. A highly sensitive issue: Helping sensitized patients requires greater regulatory flexibility.
    Knechtle SJ, Vincenti FG, Montgomery RA| | PubMed
  2. Open letter to the FDA: From priority to dead-end: Why are living donor kidney recipients blocked from novel clinical trials?
    Mannon RB, Thiessen C, Vincenti F| | PubMed
  3. Dual costimulation blockade with the CD154-specific fusion protein dazodalibep and belatacept for prophylaxis of kidney allograft rejection.
    Vincenti F, Shoji J, Wojciechowski D, Kim J, Xu W, Wilson TM, Kirk AD| | PubMed
  4. Combined Anti-CD20/Anti-CD38 Therapy in Posttransplant Focal Segmental Glomerulosclerosis Recurrence: A Retrospective, International, Multicenter Study.
    Cravedi P, Maggiore U, Mortari G, Alberici F, La Manna G, Goes N, Bouvier N, Comai G, Mehr AP, Gentile M, Palmisano A, Gessaroli E, Barbuto S, Caridi G, Bigatti C, Magnasco A, Bossini N, Kajana X, Spennacchio A, Gallon L, Ghiggeri GM, Vincenti F, Hullekes FE, Mehta RV, Riella LV, Verrina EE, Angeletti A| | PubMed
  5. Pharmacokinetics, lineage identity, and trafficking of ex vivo expanded polyclonal regulatory T cells in a prospective randomized clinical trial of kidney transplant recipients with allograft inflammation.
    Chandran S, Leung JC, Vu A, Lee K, Fitch M, Esensten JH, Shy BR, Putnam AL, Lares A, Acevedo LA, Nguyen V, Liu W, Armstrong B, Laszik ZG, Mannon RB, Friedewald JJ, Naik A, Davis S, Sarwal M, Hellerstein M, Morsheimer M, Goldstein J, Tang Q, Vincenti FG| | PubMed
  6. Dysregulated Bone Marrow Contributes to Glomerular Injury through Soluble Factors.
    Spear R, Jimenez-Uribe AP, Cao Y, Mangos S, Alcantar AG, Kim BH, Vincenti F, Reiser J, Hahm E| | PubMed
  7. Clinical events and healthcare resource utilization associated with neutropenia and leukopenia among adult kidney transplant recipients receiving valganciclovir.
    Beyer AP, Moise PA, Wong M, Gao W, Xiang C, Shen P, Pavlakis M, Vincenti F, Wang W| | PubMed
  8. Healthcare resource use and clinical events associated with neutropenia among adult kidney transplant recipients receiving valganciclovir or ganciclovir prophylaxis: a matched case-control cohort study.
    Wang W, Moise PA, Wong M, Gao W, Xiang C, Zion A, Vincenti F, Beyer AP| | PubMed
  9. Antiplasma cell antibodies: A new era of human leukocyte antigen antibody control in solid organ transplantation.
    Chandran S, Vincenti F| | PubMed
  10. Anti-HLA serologic response to CD38-targeting desensitization therapy is challenged by peripheral memory B cells in highly sensitized kidney transplant candidates.
    Torija A, Matignon M, Vincenti F, Casanova-Ferrer F, Pilon C, Tambur AR, Donadeu L, Crespo E, Kervella D, Meneghini M, Torres IB, Hafkamp F, Martinez-Lacalle A, Carrera C, Zúñiga J, Brar A, Cruzado J, Gaber AO, Lee H, Montgomery RA, Stegall M, Carmagnat M, Usureau C, Moreso F, Grimbert P, Bestard O| | PubMed